How Does Fulgent Company Work?

Fulgent Bundle

Get Full Bundle:

SWOT	~~$15~~	$10
5 FORCES	~~$15~~	$10
BCG	~~$15~~	$10
CANVAS	~~$15~~	$10
4P's MIX	~~$15~~	$10
PESTLE	~~$15~~	$10

How Does Fulgent Genetics Revolutionize Healthcare?

Fulgent Genetics, a leader in the genetic testing arena, is transforming healthcare through its innovative technology. The company provides crucial diagnostic information to physicians, impacting patient care significantly. With its advanced platform and cutting-edge DNA sequencing, Fulgent offers a wide array of services, including rare disease diagnosis and oncology solutions.

In early 2025, Fulgent Genetics expanded its reach through a strategic partnership, highlighting its commitment to growth. For those seeking a deeper understanding, this analysis will explore the operational model, revenue streams, and competitive advantages of Fulgent SWOT Analysis. Discover how Fulgent Company leverages its laboratory services to provide actionable insights in the rapidly evolving field of genetic testing and diagnostic testing.

What Are the Key Operations Driving Fulgent’s Success?

Fulgent Genetics, also known as Fulgent Company, creates value by offering comprehensive genetic testing services. Their operations are built on a proprietary technology platform that merges advanced DNA sequencing with sophisticated algorithms. This allows for the development and commercialization of a wide array of genetic tests, primarily used by physicians for clinically actionable insights.

The company's core offerings include genetic tests for rare disease diagnosis, oncology, and reproductive health. They serve various customer segments, with a focus on healthcare providers. Fulgent's operational processes involve high-throughput sequencing, data analysis, and interpretation of complex genetic information by licensed physicians.

A key aspect of Fulgent's approach is its vertically integrated model. This covers everything from sample processing to reporting, potentially leading to lower internal costs and quicker turnaround times. This integrated approach, combined with continuous technology development, translates into significant customer benefits by providing precise and actionable diagnostic information that aids in personalized treatment decisions and disease management. To learn more about the competitive landscape, you can check out Competitors Landscape of Fulgent.

Core Products and Services

Fulgent offers a wide range of genetic tests. These tests cover areas like rare diseases, oncology, and reproductive health. The company's test menu is broad and continually expanding to meet evolving medical needs.

Operational Processes

The operational processes involve high-throughput sequencing and data analysis. Interpretation of the complex genetic information is performed by licensed physicians. The company's supply chain and distribution networks are key to delivering timely and accurate results.

Value Proposition

Fulgent's value lies in providing precise and actionable diagnostic information. This helps in personalized treatment decisions and disease management. The company's integrated model and technology development contribute to efficient operations.

Strategic Partnerships

Fulgent has strategic partnerships to expand its reach. The collaboration with Foundation Medicine, announced in February 2025, is a good example. This expands the distribution of germline testing for hereditary cancers.

Key Differentiators

Fulgent's vertically integrated model is a key differentiator. This allows for efficient turnaround times and potentially lower costs. The continuous development of technology and a broad test menu also set it apart in the competitive market.

Vertically integrated model from sample processing to reporting.
Focus on continuous technology development.
Broad and expanding test menu.
Strategic partnerships to broaden market reach.

Fulgent SWOT Analysis

Complete SWOT Breakdown
Fully Customizable
Editable in Excel & Word
Professional Formatting
Investor-Ready Format

How Does Fulgent Make Money?

The primary revenue stream for Fulgent Genetics, often referred to as Fulgent Company, comes from its laboratory services. These services include precision diagnostics, anatomic pathology, and biopharma services, which are essential for healthcare providers. The company focuses on providing comprehensive genetic testing solutions.

Fulgent's monetization strategies revolve around offering comprehensive genetic testing solutions to healthcare providers. While specific innovative pricing strategies aren't detailed, the company's approach emphasizes volume growth and market penetration. Securing significant contracts and expanding its test menu are key strategies.

For the full year 2024, Fulgent's core revenue, excluding COVID-19 testing, reached $281.2 million. This represents a 7% increase compared to $262.1 million in 2023. Looking ahead to 2025, the company projects total core revenue to be approximately $310 million, indicating a 10% year-over-year growth.

2024 and 2025 Revenue Breakdown

The revenue is divided among three main segments: Precision Diagnostics, Anatomic Pathology, and Biopharma Services. The company’s revenue streams are diversified across various laboratory services, contributing to its financial performance.

In 2024, Precision Diagnostics contributed $168 million, Anatomic Pathology generated $97 million, and Biopharma Services accounted for $16 million.
For 2025, Fulgent anticipates $187 million from Precision Diagnostics, $106 million from anatomic pathology, and $17 million from biopharma services.
Fulgent secured a VA testing contract worth up to $99 million in October 2024, which is expected to contribute to revenue growth starting in 2025.
Fulgent also continues to invest in its therapeutic development business, Fulgent Pharma, which, while currently incurring cash burn, represents a future potential revenue stream from drug candidates. To learn more about the company, you can read this article about Owners & Shareholders of Fulgent.

Fulgent PESTLE Analysis

Covers All 6 PESTLE Categories
No Research Needed – Save Hours of Work
Built by Experts, Trusted by Consultants
Instant Download, Ready to Use
100% Editable, Fully Customizable

Which Strategic Decisions Have Shaped Fulgent’s Business Model?

Fulgent Genetics, or Fulgent Company, has navigated significant milestones and strategic shifts, particularly in 2024 and 2025. The company has adapted to the changing landscape of the diagnostic testing market. Its focus remains on expanding its core business and leveraging its technological strengths to maintain a competitive edge.

A key strategic move in February 2025 was the partnership with Foundation Medicine. This collaboration aims to launch FoundationOne®Germline and FoundationOne®Germline More tests in the United States. These tests, utilizing Fulgent's technology, will analyze genes associated with hereditary cancers. This partnership expands Fulgent's presence in the oncology segment of the genetic testing market, enhancing comprehensive genomic profiling for cancer patients.

Operationally, Fulgent has successfully pivoted from the decline in COVID-19 testing revenue, which was a significant revenue source during the pandemic. The company has focused on growing its core business. Full-year core revenue for 2024 grew by 7% year-over-year to $281.2 million, demonstrating its resilience and effective business streamlining.

Key Milestones

Fulgent's strategic partnership with Foundation Medicine in February 2025 to launch tests for hereditary cancers. The company has successfully managed the decline in revenue from COVID-19 testing. Fulgent's core revenue grew 7% year-over-year in 2024.

Strategic Moves

The partnership with Foundation Medicine is a key strategic move. Fulgent has focused on expanding its core business. The company continues to invest in its therapeutic pipeline.

Competitive Edge

Fulgent’s technology leadership and operational efficiency provide a competitive advantage. Its proprietary technology platform allows for a broad test menu. The company's strong financial position, with $814.6 million in cash and investments as of Q1 2025, supports strategic investments.

Financial Performance

Core revenue for 2024 grew by 7% year-over-year. The company has a strong cash position of $814.6 million as of Q1 2025. Fulgent is investing in its therapeutic pipeline for future growth.

Competitive Advantages and Future Outlook

Fulgent's competitive advantages are rooted in its proprietary technology and operational efficiency. The company's technology platform enables a broad test menu, relatively low internal costs, and competitive turnaround times. The company's strong financial position supports strategic investments.

The company's proprietary technology platform offers a broad test menu.
Fulgent maintains relatively low internal costs and competitive turnaround times.
The company's cash and investment position as of Q1 2025 was $814.6 million.
Fulgent is investing in its therapeutic pipeline, with FID-007 in Phase 2 trials and FID-022 progressing towards Phase 1.

Fulgent Business Model Canvas

Complete 9-Block Business Model Canvas
Effortlessly Communicate Your Business Strategy
Investor-Ready BMC Format
100% Editable and Customizable
Clear and Structured Layout

How Is Fulgent Positioning Itself for Continued Success?

The company holds a notable position in the genetic testing industry, offering comprehensive diagnostic information through its technology platform. Its collaborations, such as the one with Foundation Medicine, and a substantial VA testing contract, highlight its ability to secure significant business in a competitive market. The focus on precision diagnostics and biopharma services provides a diversified approach within the healthcare sector, which is essential for understanding Fulgent Genetics's target market.

However, the company faces challenges, including profitability concerns, with a reported GAAP loss of $42.7 million for 2024. Revenue volatility, especially in biopharma services, and regulatory changes, such as those impacting lab-developed tests (LDTs), pose operational risks. Despite these challenges, the company is working on strategies to sustain and expand its revenue-generating capabilities.

Industry Position

The company is positioned in the genetic testing and diagnostic testing market. It leverages its technology platform to provide comprehensive diagnostic information. Partnerships and significant contracts, like the VA testing deal, show its relevance.

Risks

Profitability is a concern, with a GAAP loss of $42.7 million in 2024 and $11.5 million in Q1 2025. Revenue volatility, particularly in biopharma, poses a risk. Regulatory changes and uncertainties in clinical trials could also impact operations.

Future Outlook

The company's core revenue guidance for 2025 is approximately $310 million, reflecting a 10% year-over-year growth. Expansion of sales and marketing teams and potential M&A activity are planned. Therapeutic pipeline development is a long-term strategy.

Financial Data

For the full year 2024, the company reported a GAAP loss of $42.7 million. Non-GAAP operating margins are projected to be around -15% for 2025. The company reiterated its full-year 2025 core revenue guidance at approximately $310 million.

Strategic Initiatives

The company plans to expand its sales and marketing teams and is actively evaluating merger and acquisition opportunities to enhance its distribution network and technology deployment. The development of its therapeutic pipeline is a long-term strategy.

Expansion of sales and marketing teams.
Evaluation of merger and acquisition opportunities.
Development of the therapeutic pipeline.
Focus on precision diagnostics, particularly reproductive health testing.

Fulgent Porter's Five Forces Analysis

Covers All 5 Competitive Forces in Detail
Structured for Consultants, Students, and Founders
100% Editable in Microsoft Word & Excel
Instant Digital Download – Use Immediately
Compatible with Mac & PC – Fully Unlocked

Related Blogs

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.